Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry

OBJECTIVE: Successful uptake of biosimilars in rheumatology is limited by lack of real-world evidence regarding effectiveness of biosimilar-to-biosimilar switching. We investigated infliximab biosimilars CT-P13-to-GP1111 switching among patients with rheumatoid arthritis (RA), psoriatic arthritis (P...

Descripción completa

Detalles Bibliográficos
Autores principales: Nabi, Hafsah, Hendricks, Oliver, Jensen, Dorte Vendelbo, Loft, Anne Gitte, Pedersen, Jens Kristian, Just, Søren Andreas, Danebod, Kamilla, Munk, Heidi Lausten, Kristensen, Salome, Manilo, Natalia, Colic, Ada, Linauskas, Asta, Thygesen, Pia Høger, Christensen, Louise Brot, Kalisz, Maren Høgberget, Lomborg, Niels, Chrysidis, Stavros, Raun, Johnny Lillelund, Andersen, Marlene, Mehnert, Frank, Krogh, Niels Steen, Hetland, Merete Lund, Glintborg, Bente
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Inflammatory Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685195/
https://www.ncbi.nlm.nih.gov/pubmed/36418087
http://dx.doi.org/10.1136/rmdopen-2022-002560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685195/
https://www.ncbi.nlm.nih.gov/pubmed/36418087
http://dx.doi.org/10.1136/rmdopen-2022-002560

Ejemplares similares